Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "innovaTV 301/ENGOT-cx12/GOG-3057 Study - Tisotumab Vedotin vs. Investigator’s Choice of Chemo in 2L/3L Recurrent or Metastatic Cervical Cancer"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Susana Banerjee
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Susana Banerjee
Login to view comments.
Click here to Login
Gynecologic